chronic spontaneous urticaria

target reach ladder climb meet win beat competition

Celldex anti-cKIT antibody reduces hives in another phase 2 test

The latest phase 2 success follows a mid-phase trial in chronic spontaneous uticaria that read out in November 2023.

James Waldron Jul 30, 2024 5:50am

ducks in a row line up follow leader

Novartis lines up another potential indication for BTK inhibitor

Mar 9, 2024 12:00pm

Sanofi

Sanofi BTK inhibitor readout in chronic hives sets up ph. 3 push

Feb 26, 2024 10:35am

Asthma inhaler

Jasper eyes next indication for hive drug, thanks to mouse data

Feb 26, 2024 6:00am

Graphic showing arrows missing the bullseye on a target

Allakos drops lead asset after midphase flops, halves headcount

Jan 16, 2024 9:26am

soccer kick off ball football field play game crowd boots cleats

Celldex laces up next to Big Pharmas with chronic hive drug

Nov 6, 2023 10:17am